Please assess the completion status of the following clinical trial:

Trial Title: Clinical Evaluation of MDT-2111 in Subjects With Symptomatic Severe Aortic Stenosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject must have co-morbidities such that one cardiologist and one cardiac surgeons agree that medical factors preclude operation, based on a conclusion that the probability of death or serious morbidity exceeds the probability of meaningful improvement.~2. Subject has senile degenerative aortic valve stenosis with:~   mean gradient \> 40 mmHg or jet velocity greater than 4.0 m/s by either resting or dobutamine stress echocardiogram, or simultaneous pressure recordings at cardiac catheterization (either resting or dobutamine stress), AND an initial aortic valve area of ≤ 0.8 cm² (or aortic valve area index ≤ 0.5 cm²/m²) by resting echocardiogram.~3. Subject is symptomatic from his/her aortic valve stenosis, as demonstrated by NYHA Functional Class Class III or greater. If screening committee agrees the eligibility of a patient with class II , based on medical factors, he/she can be enrolled.~4. Subject has been informed of the nature of the trial and has signed an Informed Consent Form.~5. Subject agrees to comply with specified follow-up evaluations and to return to the same investigational site where the procedure was performed.~Exclusion Criteria:~1. Evidence of an acute myocardial infarction ≤ 30 days prior to the intended treatment.~2. Any percutaneous coronary or peripheral interventional procedure performed within 30 days prior to the procedure.~3. Blood dyscrasias as defined:~   * Leukopenia (WBC count \< 1,000 cells/mm³)~  * Thrombocytopenia (platelet count \<50,000 cells/mm³)~  * History of bleeding diathesis or coagulopathy~  * Hypercoagulable states~4. Untreated clinically significant coronary artery disease requiring revascularization.~5. Cardiogenic shock manifested by low cardiac output, vasopressor dependence, or mechanical hemodynamic support.~6. Need for emergency surgery for any reason.~7. Severe ventricular dysfunction with left ventricular ejection fraction (LVEF) \< 20% as measured by resting echocardiogram.~8. Recent (within 6 months) cerebrovascular accident (CVA) or transient ischemic attack(TIA).~9. End stage renal disease requiring chronic dialysis.~10. GI bleeding within the past 3 months.~11. A known hypersensitivity or contraindication to any of the following which cannot be adequately pre-medicated:~    * Aspirin~   * Ticlopidine~   * Heparin~   * Contrast media~   * Nitinol (titanium and nickel alloy)~12. Ongoing sepsis, including active endocarditis.~13. Subject refuses a blood transfusion.~14. Life expectancy \< 12 months due to associated non-cardiac co-morbid conditions.~15. Other medical, social, or psychological conditions that in the opinion of an Investigator precludes the subject from appropriate consent.~16. Severe dementia (resulting in either inability to provide informed consent for the trial/procedure, prevents independent lifestyle outside of a chronic care facility, or will fundamentally complicate rehabilitation from the procedure or compliance with follow-up visits).~17. Currently participating in an investigational drug or another device trial. Note: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials.~18. Symptomatic carotid or vertebral artery disease.~19. Native aortic annulus size \< 20 mm or \> 27 mm per the screening diagnostic imaging.~20. Pre-existing prosthetic heart valve in any position.~21. Mixed aortic valve disease (aortic stenosis and aortic regurgitation with predominant aortic regurgitation).~22. Mitral regurgitation (moderate to severe) or severe tricuspid regurgitation.~23. Moderate to severe mitral stenosis.~24. Hypertrophic obstructive cardiomyopathy.~25. Echocardiographic evidence of intracardiac mass, thrombus or vegetation.~26. Severe basal septal hypertrophy with an outflow gradient.~27. Ascending aorta diameter \> 43 mm (in case of the aortic annulus is 23-27 mm) unless the aortic annulus is 20-23 mm in which case the ascending aorta diameter \> 40 mm.~28. Congenital bicuspid or unicuspid valve verified by echocardiography.~29. For patients with native coronary artery dependent circulation:~    * Sinus of valsalva width \< 29 mm unless the aortic annulus is 20-23 mm, in which case the sinus of valsalva width \< 27 mm, OR~   * Height of the left or right coronary sinus of valsalva (to the tubular aorta) \< 15mm.~30. Femoral or iliac artery of the first choice corresponding to any one of the followings:~    * Angle at aortic root (the angle between aortic valve annulus plane and horizontal plane/vertebra) exceeds 70°.~   * Vessel diameter of femoral or iliac artery is less than 6 mm.~   * Aorta has severe calcification, excess tortuosity or severe atherosclerosis.~   * Transarterial access not able to accommodate an 18Fr sheath.~31. Subclavian artery of the second choice corresponding to any one of the followings:~    * Angle at aortic root (the angle between aortic valve annulus plane and horizontal plane/vertebra) exceeds 70° (in the case of left subclavian artery) and 30° (in the case of right subclavian artery).~   * Vessel diameter of subclavian artery is less than 6 mm.~   * Transarterial access not able to accommodate an 18Fr sheath.~32. Direct Aortic Artery as third line choice of access. Patients are excluded from Direct Aortic access if:~    * Access site is less than 6 cm from the aortic valve basal plane~   * Access site has calcification or porcelain aorta~   * Access site and delivery trajectory contain RIMA or patent RIMA graft

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MDT-2111 CoreValve TAVI (Type: EXPERIMENTAL): Transcatheter Aortic Valve Implantation (TAVI) with MDT-2111 CoreValve system. Access sites for the implant include: Iliofemoral, Subclavian and Direct Aortic.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete